U.S. Earnings Preview: Before Market Open May 13

Dow Jones
05/13

This article was automatically generated by Dow Jones using technology from Automated Insights.

The following companies are among those expected to report their latest financial results before the market opens.

Dynatrace Inc.'s fourth-quarter EPS is forecast at 15 cents, compared with 13 cents in the prior-year period. Adjusted EPS is forecast at 39 cents.

Global-E Online Ltd.'s first-quarter EPS is forecast at 17 cents, compared with a loss of 11 cents in the prior-year period.

Vishay Intertechnology Inc.'s first-quarter EPS is forecast at 3 cents. Adjusted EPS is forecast at 2 cents.

National Vision Holdings Inc.'s first-quarter EPS is forecast at 16 cents, compared with 18 cents in the prior-year period. Adjusted EPS is forecast at 43 cents.

Cabaletta Bio Inc.'s first-quarter EPS is forecast at a loss of 43 cents, compared with a loss of 71 cents in the prior-year period. Adjusted EPS is forecast at a loss of 40 cents.

Altimmune Inc.'s first-quarter EPS is forecast at a loss of 25 cents, compared with a loss of 26 cents in the prior-year period. Adjusted EPS is forecast at a loss of 24 cents.

Larimar Therapeutics Inc.'s first-quarter EPS is forecast at a loss of 49 cents, compared with a loss of 46 cents in the prior-year period. Adjusted EPS is forecast at a loss of 53 cents.

Protara Therapeutics Inc.'s first-quarter EPS is forecast at a loss of 37 cents, compared with a loss of 29 cents in the prior-year period.

Humacyte Inc.'s first-quarter EPS is forecast at a loss of 11 cents, compared with net income of 28 cents per share in the prior-year period. Adjusted EPS is forecast at a loss of 12 cents.

Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.

 

(END) Dow Jones Newswires

May 13, 2026 05:31 ET (09:31 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10